Pharma Stocks Are Bleeding. But These 2 Look Like Bargains.

  • 📰 MarketWatch
  • ⏱ Reading Time:
  • 60 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 27%
  • Publisher: 97%

المملكة العربية السعودية أخبار أخبار

المملكة العربية السعودية أحدث الأخبار,المملكة العربية السعودية عناوين

With many drugmakers struggling, it could be a good time to buy.

Investors have mostly had one reaction to drugmakers’ earnings this quarter: Slam that big red “sell” button, and slam it hard.

The latest no good, very bad earnings season started with Johnson & Johnson , which on Oct. 17 raised its full-year guidance and announced third quarter earnings that beat Wall Street estimates. Shares fell 0.9% anyhow, eventually sliding to a 52-week low on October 27. The selloffs came at a low ebb in investor sentiment around big pharma, with the exception of the two companies behind the new anti-obesity drugs, Eli Lilly and Novo Nordisk . While Lilly’s shares are up 55.8% this year, and Novo’s are up 45.5%, the rest of the sector is trailing the market. In a year when the S&P 500 is up 13.5%, Pfizer is down 39%, Bristol Myers down 26.7%, Merck down 6.6%, and Johnson & Johnson down14.3%.

Despite all those headwinds, shares of a few of the drugmakers still seem cheap, especially after the recent selloffs. One is Merck. “We see MRK’s diversified pipeline/portfolio…as being increasingly well-equipped with commercial opportunities with the potential to generate sustained growth over the intermediate and longer term,” Goldman Sachs analyst Chris Shibutani wrote in an October 27 note. Shibutani has a Buy rating and a $131 target price on the stock.

 

شكرًا لك على تعليقك. سيتم نشر تعليقك بعد مراجعته.
لقد قمنا بتلخيص هذا الخبر حتى تتمكن من قراءته بسرعة. إذا كنت مهتمًا بالأخبار، يمكنك قراءة النص الكامل هنا. اقرأ أكثر:

 /  🏆 3. in SA

المملكة العربية السعودية أحدث الأخبار, المملكة العربية السعودية عناوين

Similar News:يمكنك أيضًا قراءة قصص إخبارية مشابهة لهذه التي قمنا بجمعها من مصادر إخبارية أخرى.

Stocks vs. Gold: Where to Place Your November Bets for Maximum Gains?Market Overview Analysis by Investing.com (Ismael De La Cruz) covering: XAU/USD, S&P 500, iShares Core S&P 500 ETF, SPDR® S&P 500. Read Investing.com (Ismael De La Cruz)'s latest article on Investing.com
مصدر: Investingcom - 🏆 450. / 53 اقرأ أكثر »

12 Warren Buffett Style Dividend Stocks With A Margin Of SafetyI am the editor of three Forbes investment newsletters: Forbes Dividend Investor, Forbes Billionaire Investor and covered call writing advisory service, Forbes Premium Income Report. Prior to joining Forbes in 2001, I was a producer and reporter at CNN Financial News, focusing on stories about entrepreneurship.
مصدر: Forbes - 🏆 394. / 53 اقرأ أكثر »

Stocks enjoy best week in a yearA perfect combination of data, Fedspeak and earnings are putting wind in Wall Street's sails.
مصدر: axios - 🏆 302. / 63 اقرأ أكثر »